Rituxan 500 MG/50 ML vial 50ML
Ended Awarded Last action
- Contract number
- SPE2DR26FFBX4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,845
Award facts
- Contract value 100% obligated
- $11,844.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,844.88 to DMS Pharmaceutical Group Inc. on January 15, 2026, for the supply of Rituxan 500 mg/50 ml vials. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform the delivery order at its facility in Park Ridge. This award was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The delivery order is scheduled for ultimate completion by February 6, 2026, and utilizes firm fixed-price contracting with no identified subcontractor relationships.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. That parent contract, valued at $499.999 billion with a completion date of December 31, 2036, was awarded on November 13, 2025, and authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products to support Department of Defense military healthcare facilities worldwide. The PPV-G GEN V is part of the broader $30.3 billion pharmaceutical prime vendor acquisition strategy, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supplying critical pharmaceutical and medical consumable support to the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FFBX4?
SPE2DR26FFBX4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 15, 2026.
How much is contract SPE2DR26FFBX4 worth?
The government has obligated $11,845 on SPE2DR26FFBX4.
Is contract SPE2DR26FFBX4 an order under another contract?
Yes. SPE2DR26FFBX4 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBX4 competed?
The extent of competition for SPE2DR26FFBX4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award